[Combination chemotherapy of S-1 plus biweekly docetaxel for advanced and recurrent gastric cancer].
The S-1 +biweekly docetaxel (DOC) combination therapy was evaluated for advanced or recurrent gastric cancer patients. This combination therapy was evaluated in vitro using the nude rat-gastric cancer xenograft system. S-1 alone or DOC alone showed antitumor activity, and the antitumor activity was synergistic when two drugs were combined. In clinical settings, the schedule was S-1 80 mg/m2 (day 1-14, orally) and DOC (day 1 and day 15, intravenously) followed by a 2-week rest. In phase I study, the dose of DOC was evaluated, and a recommended dose for phase II was determined as 35 mg/m2. The entry for phase II study was completed, and the preliminary results of 33 patients showed the response rate of 21.2%. The incidence of more than grade 3 adverse effects was 29%(neutropenia, leukocytopenia, anorexia and mucositis). The S-1 +biweekly DOC combination therapy can be a candidate for outpatient chemotherapy for advanced or recurrent gastric cancer.
Takahashi
Ikuo
I
Dept of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Japan.
Oki
Eiji
E
Egashira
Akinori
A
Morita
Masaru
M
Kakeji
Yoshihiro
Y
Maehara
Yoshihiko
Y
D000818:Animals; D000855:Anorexia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D000077143:Docetaxel; D004338:Drug Combinations; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D009368:Neoplasm Transplantation; D009503:Neutropenia / Q000139:chemically induced; D010094:Oxonic Acid / Q000008:administration & dosage / Q000009:adverse effects; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D011923:Rats, Nude; D013274:Stomach Neoplasms / Q000188:drug therapy*; D013280:Stomatitis / Q000139:chemically induced; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects
D004338:Drug Combinations; D043823:Taxoids; C079198:S 1 (combination); D005641:Tegafur; D000077143:Docetaxel; D010094:Oxonic Acid